drugset / Trial / NCT00718887
Suboptimal Responders to Adefovir Switching to Entecavir
RandomizedCrossoverOpen-labelTreatment
Summary
Switching to Entecavir will result in superior antiviral efficacy as compared to continuing with Adefovir in patients with a suboptimal response to Adefovir
Timeline
- Start
- 2008-07
- Primary completion
- 2009-12
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adefovir | Unknown | 10 mg | Oral |
| Subject | Entecavir | Small molecule | 0.5 mg | Oral |